Item 8.01 Other Events.

On May 13, 2021, Heron Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved ZYNRELEFTM (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty, as described in the press release furnished herewith as Exhibit 99.1.

A copy of presentation materials, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished as Exhibit 99.2 hereto. The attached materials have also been posted on the Company's website at www.herontx.com. The Company does not undertake any obligation to update this presentation.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.   Description

99.1            Press Release, dated May 13, 2021
99.2            Corporate Presentation, dated May 13, 2021
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses